Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik Muser

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Journal of Medical Economics|June 15, 2019
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasisAmanda Teeple, Erik Muser
Journal of Medical Economics|July 3, 2019
Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasisQian Cai, Amanda Teeple, Bingcao Wu, et al.
Journal of Medical Economics|February 16, 2012
The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost savingNatalie C Edwards, Erik Muser, Dilesh Doshi, et al.
Drugs - Real World Outcomes|June 17, 2021
Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USAZhijie Ding, Camilo Obando, Erik Muser, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2014
Methodological considerations in estimating adherence and persistence for a long-acting injectable medicationElizabeth J Campagna, Erik Muser, Joseph Parks, et al.
Current Medical Research and Opinion|April 27, 2022
Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databasesJanvi Sah, Amanda Teeple, Erik Muser, et al.
Journal of Medical Economics|October 1, 2014
Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysisIris Lin, Erik Muser, Michael Munsell, et al.
Journal of Medical Economics|June 20, 2013
Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophreniaKathleen Lang, Victoria Federico, Erik Muser, et al.
Journal of Occupational and Environmental Medicine|May 13, 2008
An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney diseaseFrank Papatheofanis, Brahim K Bookhart, Erik Muser, et al.
Journal of Clinical Psychopharmacology|August 16, 2016
Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United StatesKruti Joshi, Jay Lin, Melissa Lingohr-Smith, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Journal of Medical Economics|June 15, 2019
Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasisAmanda Teeple, Erik Muser
Journal of Medical Economics|July 3, 2019
Prevalence and economic burden of comorbid anxiety and depression among patients with moderate-to-severe psoriasisQian Cai, Amanda Teeple, Bingcao Wu, et al.
Journal of Medical Economics|February 16, 2012
The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost savingNatalie C Edwards, Erik Muser, Dilesh Doshi, et al.
Drugs - Real World Outcomes|June 17, 2021
Real-World Persistence, Maintenance Dosing, and Pre-Post Corticosteroid and Opioid Use Among Crohn's Disease Patients with Prescription Claims for Ustekinumab in the USAZhijie Ding, Camilo Obando, Erik Muser, et al.
Journal of Managed Care & Specialty Pharmacy|June 27, 2014
Methodological considerations in estimating adherence and persistence for a long-acting injectable medicationElizabeth J Campagna, Erik Muser, Joseph Parks, et al.
Current Medical Research and Opinion|April 27, 2022
Treatment persistence and maintenance dose titration among ulcerative colitis patients on biologics: a pooled study of three United States claim databasesJanvi Sah, Amanda Teeple, Erik Muser, et al.
Journal of Medical Economics|October 1, 2014
Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysisIris Lin, Erik Muser, Michael Munsell, et al.
Journal of Medical Economics|June 20, 2013
Rates and predictors of antipsychotic non-adherence and hospitalization in Medicaid and commercially-insured patients with schizophreniaKathleen Lang, Victoria Federico, Erik Muser, et al.
Journal of Occupational and Environmental Medicine|May 13, 2008
An examination of productivity and resource utilization associated with epoetin alfa treatment in employees with predialysis chronic kidney diseaseFrank Papatheofanis, Brahim K Bookhart, Erik Muser, et al.
Journal of Clinical Psychopharmacology|August 16, 2016
Treatment Patterns and Antipsychotic Medication Adherence Among Commercially Insured Patients With Schizoaffective Disorder in the United StatesKruti Joshi, Jay Lin, Melissa Lingohr-Smith, et al.
Pageof 5